Repotrectinib in a Patient With Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2024 Jan 25

PMID 38271657

Authors

Karen M Yun

Anna Narezkina

Charles Redfern

Katherine Velasco

Lyudmila Bazhenova

Affiliations

Soon will be listed here.

Abstract

Repotrectinib in a patient with NTRK fusion-positive pancreatic carcinoma and congenital long QT syndrome.

Citing Articles

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.

Elhariri A, Patel J, Mahadevia H, Albelal D, Ahmed A, Jones J Target Oncol. 2024; 19(5):679-689.

PMID: 39123077 DOI: 10.1007/s11523-024-01088-3.

References

Porta-Sanchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K . Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017; 6(12). PMC: 5779062. DOI: 10.1161/JAHA.117.007724. View

Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019; 21(2):271-282. PMC: 7461630. DOI: 10.1016/S1470-2045(19)30691-6. View

Krahn A, Laksman Z, Sy R, Postema P, Ackerman M, Wilde A . Congenital Long QT Syndrome. JACC Clin Electrophysiol. 2022; 8(5):687-706. DOI: 10.1016/j.jacep.2022.02.017. View

Drilon A, Ou S, Cho B, Kim D, Lee J, Lin J . Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018; 8(10):1227-1236. DOI: 10.1158/2159-8290.CD-18-0484. View

Pishvaian M, Garrido-Laguna I, Liu S, Multani P, Chow-Maneval E, Rolfo C . Entrectinib in and Fusion-Positive Metastatic Pancreatic Cancer. JCO Precis Oncol. 2022; 2:1-7. DOI: 10.1200/PO.18.00039. View

Drilon A, Laetsch T, Kummar S, Dubois S, Lassen U, Demetri G . Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8):731-739. PMC: 5857389. DOI: 10.1056/NEJMoa1714448. View

Giraud E, Ferrier K, Lankheet N, Desar I, Steeghs N, Beukema R . The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022; 23(9):e406-e415. DOI: 10.1016/S1470-2045(22)00221-2. View

Drew B, Ackerman M, Funk M, Gibler W, Kligfield P, Menon V . Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010; 55(9):934-47. PMC: 3057430. DOI: 10.1016/j.jacc.2010.01.001. View

Al-Khatib S, Stevenson W, Ackerman M, Bryant W, Callans D, Curtis A . 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and.... J Am Coll Cardiol. 2017; 72(14):e91-e220. DOI: 10.1016/j.jacc.2017.10.054. View

10.

Cocco E, Scaltriti M, Drilon A . NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15(12):731-747. PMC: 6419506. DOI: 10.1038/s41571-018-0113-0. View

11.

Hong D, Dubois S, Kummar S, Farago A, Albert C, Rohrberg K . Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020; 21(4):531-540. PMC: 7497841. DOI: 10.1016/S1470-2045(19)30856-3. View

12.

Demetri G, De Braud F, Drilon A, Siena S, Patel M, Cho B . Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022; 28(7):1302-1312. PMC: 9365368. DOI: 10.1158/1078-0432.CCR-21-3597. View

13.

OReilly E, Hechtman J . Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 2019; 30(Suppl_8):viii36-viii40. PMC: 6859823. DOI: 10.1093/annonc/mdz385. View

14.

Cocco E, Schram A, Kulick A, Misale S, Won H, Yaeger R . Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019; 25(9):1422-1427. PMC: 6736691. DOI: 10.1038/s41591-019-0542-z. View

15.

Pishvaian M, Bender R, Halverson D, Rahib L, Hendifar A, Mikhail S . Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res. 2018; 24(20):5018-5027. DOI: 10.1158/1078-0432.CCR-18-0531. View

16.

Gupta M, Sherrow C, Krone M, Blais E, Pishvaian M, Petricoin E . Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. J Natl Compr Canc Netw. 2021; 19(1):10-15. PMC: 8765083. DOI: 10.6004/jnccn.2020.7641. View